Cas:1196-09-4 5-Bromo-3-methyl-1-benzothiophene manufacturer & supplier

Chemical Name:5-Bromo-3-methyl-1-benzothiophene

CAS.NO:1196-09-4

Synonyms:5-bromo-3-methylbenzothiophene;5-Bromo-3-methyl-benzo[b]thiophene;Benzo[b]thiophene, 5-bromo-3-methyl-;5-Bromo-3-methyl-1-benzothiophene

Molecular Formula:C₉H₇BrS

Molecular Weight:227.121

HS Code:2934999090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:302.3±22.0 °C at 760 mmHg

Density:1.6±0.1 g/cm3

Index of Refraction:1.680

PSA:28.24000

Exact Mass:225.945175

LogP:5.61

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-bromo-3-methylbenzothiophene chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-Bromo-3-methyl-1-benzothiophene physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-bromo-3-methylbenzothiophene Use and application,Benzo[b]thiophene, 5-bromo-3-methyl- technical grade,usp/ep/jp grade.

Related News: First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 5-Bromo-3-methyl-1-benzothiophene manufacturer First up is Lilly, which reached all-time highs this week as attention turned to its once highly hyped donanemab, another anti-amyloid that saw a mixed bag of data back in March, with a slight win on one disease scale undermined by a failure on a more widely used measure of Alzheimer’s. 5-Bromo-3-methyl-1-benzothiophene supplier The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study. 5-Bromo-3-methyl-1-benzothiophene vendor Additional results from the trial with data on another goal of extending survival is expected in 2020, AstraZeneca said. 5-Bromo-3-methyl-1-benzothiophene factory Toxic forever chemicals have no place in personal care products,” Scott Faber, EWG’s senior vice president of government affairs. “PFAS have been linked to serious health problems, including cancer and harm to the reproductive and immune systems. EWG applauds Sen. Collins and Rep. Dingell for introducing the No PFAS in Cosmetics Act.